CG Oncology officer plans $3.8M stock sale

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) received a notice under Rule 144 from officer Ambaw Bellete covering a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $3,775,250.00 and 88,640,375 shares outstanding as of 08/31/2026.

The shares are to be sold on or after 08/31/2026 in connection with a stock option exercise for cash. The notice also lists multiple prior sales of CG Oncology common stock by Ambaw Bellete during the past three months, including several transactions of tens of thousands of shares.

Key Figures

Shares to be sold: 50,000 shares of common stock Aggregate market value of securities to be sold: $3,775,250.00 Shares outstanding: 88,640,375 shares +4 more

7 metrics

Shares to be sold 50,000 shares of common stock Proposed Rule 144 sale by Ambaw Bellete

Aggregate market value of securities to be sold $3,775,250.00 Value of 50,000 CG Oncology shares covered by the notice

Shares outstanding 88,640,375 shares Common stock outstanding as of 08/31/2026

Proposed sale date 08/31/2026 Date for the Rule 144 sale and stock option exercise

Past sale on 08/19/2026 100,000 shares for $7,954,105.00 One of the securities sold during the past 3 months

Past sale on 08/17/2026 52,438 shares for $4,034,894.35 Securities sold during the past 3 months

Past sale on 08/10/2026 50,000 shares for $3,770,580.00 Securities sold during the past 3 months

Key Terms

Rule 144, stock option exercise, aggregate market value, securities to be sold, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"Common | 08/31/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 50000 | 3775250.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

securities to be sold financial

"144: Securities To Be Sold"

securities sold during the past 3 months financial

"144: Securities Sold During The Past 3 Months"

FAQ

What transaction is Ambaw Bellete reporting for CGON in this Form 144?

Ambaw Bellete is reporting a proposed sale of 50,000 shares of CG Oncology, Inc. common stock under Rule 144, to be executed through Morgan Stanley Smith Barney LLC in connection with a stock option exercise for cash on or after 08/31/2026.

How large is the proposed Rule 144 sale for CGON in dollar terms?

The proposed Rule 144 sale by Ambaw Bellete covers 50,000 shares of CG Oncology common stock with an aggregate market value of $3,775,250.00, as stated in the securities information section of the notice.

How many CGON shares were outstanding as of the Form 144 date?

As of 08/31/2026, CG Oncology, Inc. reports 88,640,375 shares of common stock outstanding. This figure provides context for the size of the proposed Rule 144 sale.

What is the nature of the CGON shares to be sold by Ambaw Bellete?

The CG Oncology, Inc. shares to be sold are common stock that will be issued upon a stock option exercise. The Form 144 indicates that this option exercise will be paid in cash and that the resulting shares may be sold under Rule 144.

On which market are the CGON shares in this Form 144 listed?

The common stock of CG Oncology, Inc. referenced in this Form 144 is listed on the NASDAQ market, as specified in the securities information section.

What prior CGON stock sales by Ambaw Bellete are disclosed in the past 3 months?

The notice lists multiple prior sales of CG Oncology common stock by Ambaw Bellete over the past three months, including a sale of 100,000 shares for $7,954,105.00 on 08/19/2026 and several other transactions involving tens of thousands of shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 04:51 PM Accepted by SEC EDGAR 08/31/2026 - 04:50 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002007090
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CG ONCOLOGY, INC.
SEC File Number	001-41925
Address of Issuer	3000 Pegasus Park Drive SUITE 1640 Dallas TEXAS 75247
Phone	(949) 409-3700
Name of Person for Whose Account the Securities are To Be Sold	AMBAW BELLETE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	50000	3775250.00	88640375	08/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/31/2026	Stock Option Exercise	Issuer			50000	08/31/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/27/2026	5789	459560.92
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/25/2026	10551	839338.38
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/24/2026	5762	458185.02
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/19/2026	100000	7954105.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/17/2026	52438	4034894.35
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/14/2026	19364	1452635.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/13/2026	25989	1973970.86
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/12/2026	32137	2526514.53
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/11/2026	50000	3810255.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/10/2026	50000	3770580.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/07/2026	9250	696062.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/06/2026	75000	5672212.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/05/2026	25000	1837500.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/29/2026	4303	316270.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/28/2026	50000	3625195.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/27/2026	50000	3627995.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/23/2026	50000	3588620.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/15/2026	52438	3816007.65

144: Remarks and Signature

Remarks
Date of Notice	08/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ambaw Bellete
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)